Synthesis of N3,5′-cyclo-4-(β-D-ribofuranosyl)-vic- triazolo[4,5-b]pyridin-5-one and its 3′-deoxysugar analogue as potential anti-hepatitis C virus agents

Peiyuan Wang, Laurent Hollecker, Krzysztof W Pankiewicz, Steven E. Patterson, Tony Whitaker, Tamara R. McBrayer, Phillip M. Tharnish, Lieven J. Stuyver, Raymond F. Schinazi, Michael J. Otto, Kyoichi A. Watanabe

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

We recently discovered a novel compound, identified as N 3,5′-cyclo-4-(β-D-ribofuranosyl)-vic-triazolo[4,5-b] pyridinin-5-one, with anti-hepatitis C virus (HCV) activity in vitro. The structure was confirmed by chemical synthesis from 2-hydroxy-5-nitropyridine. It showed anti-HCV activity with EC50 = 19.7 μM in replicon cells. Its 3′-deoxy sugar analogue was also synthesized, but was inactive against HCV in vitro.

Original languageEnglish (US)
Pages (from-to)957-960
Number of pages4
JournalNucleosides, Nucleotides and Nucleic Acids
Volume24
Issue number5-7
DOIs
StatePublished - 2005
Externally publishedYes

Bibliographical note

Funding Information:
Supported in parts by NIH grants 1R43 AI-52868 (biology) and 1 R43 AI-056720 (chemistry). We would like to acknowledge the contribution of D. L. Barnard, J. D. Morrey, and D. F. Smee at the Institute for Antiviral Research at Utah State University for their testing of RNA viruses under NIH Contract No. N01-A1-85348. Dr. Schinazi is a founder and consultant of Pharmasset, Inc. His laboratory did not receive any funding from Pharmasset, Inc.

Fingerprint

Dive into the research topics of 'Synthesis of N<sup>3</sup>,5′-cyclo-4-(β-D-ribofuranosyl)-vic- triazolo[4,5-b]pyridin-5-one and its 3′-deoxysugar analogue as potential anti-hepatitis C virus agents'. Together they form a unique fingerprint.

Cite this